Pharmaceuticals Market Research Reports & Industry Analysis
Pharmaceuticals Industry Research & Market Reports
-
Global Cancer Immunotherapy Market Analysis & Forecast to 2023 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cel
... Analysis & Forecast to 2023 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors Read More
-
Infectious Disease Testing Instrumentation: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics - Latest Microbiology Analyzers and Strategic Profiles of Leading Suppliers
... testing, including their operating characteristics, features and selling prices. The report also presents strategic assessments of leading microbiology market players and emerging suppliers with innovative technologies and products, including their sales, product portfolios, distribution tactics, ... Read More
-
Tumor Markers Testing Instrumentation: Cancer Diagnostic Analyzers and Strategic Profiles of Leading Suppliers
... The report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 119 ... Read More
-
Cancer Diagnostic Instrumentation: Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers
... for tumor marker testing. Contains 25 pages Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch. Read More
-
Hematology and Flow Cytometry Instrumentation: Latest Analyzers and Strategic Profiles of Leading Suppliers
... strategic assessments of current and emerging suppliers of hematology and flow cytometry products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Contains 65 pages Please ... Read More
-
Cancer Diagnostic Instrumentation: Tumor Marker Testing Analyzers and Strategic Profiles of Leading Suppliers
... The report also presents strategic assessments of current and emerging suppliers of tumor marker diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains ... Read More
-
Emerging Cancer Diagnostic Technologies and Market Applications
... diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. Contains 110 pages Please note: The delivery time for the electronic version of this report is ... Read More
-
Emerging Cancer Diagnostic Technologies and Strategic Profiles of Leading Suppliers
... potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. The report also presents strategic assessments of current and emerging suppliers of ... Read More
-
Spain Pharmaceuticals & Healthcare Q1 2020
... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More
-
United Arab Emirates Pharmaceuticals & Healthcare Q1 2020
... of private healthcare coverage and the modernisationof health infrastructure will contribute to drive prescription market growth. Stricter pricing controls, generic drug substitution and anunfavourable demographic profile will cause headwinds to firms over the coming years. Read More
-
Vietnam Pharmaceuticals & Healthcare Q1 2020
... schemes, andauthorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground for substantialvolume and value growth. However, this potential will mostly attract generic drug companies, given the low ... Read More
-
Puerto Rico Pharmaceuticals & Healthcare Q1 2020
... pressure on the high medicine pricing is becoming moreintense. The financial sustainability of Puerto Rico’s healthcare sector is increasingly under pressure. There are significant economicheadwinds, along with recent political upheavals. Sales of pharmaceuticals and healthcare ... Read More
-
Serbia Pharmaceuticals & Healthcare Q1 2020
... affordability levels, weak access to healthcare and a challenging regulatory environment. However, increasing purchasing poweramid rising real wages along with an ageing population and a rising chronic disease burden will provide long-term growth prospectsfor drugmakers. Read More
-
Cuba Pharmaceuticals & Healthcare Q1 2020
... into commercial opportunities fordrugmakers in the long term, a poor intellectual property environment with limited respect for patents and a strong domesticpharmaceutical industry weaken prospects for innovative drugs sales. Furthermore, emigration and a shrinking working-agepopulation ... Read More
-
Lithuania Pharmaceuticals & Healthcare Q1 2020
... its small population size and thus, limited growth potential willcontinue to hinder commercial opportunities in its pharmaceutical market. Nevertheless, the wide reimbursement coverageremains a draw for multinationals that operate regionally and bid for government tenders.. Read More
-
Malaysia Pharmaceuticals & Healthcare Q1 2020
... a non-transparent process to issue compulsorylicenses will continue to undermine investment by innovative drugmakers in the country. Furthermore, the Malaysianpharmaceutical market will be faced with a myriad of challenges in Malaysia, including weak intellectual property ... Read More
-
Mexico Pharmaceuticals & Healthcare Q1 2020
... access to healthcare services andmedications through a new public health trust, although the financing for this additional coverage is still not sufficiently clear whilethe transition phase pose downside risk to access to treatment. In response ... Read More
-
Peru Pharmaceuticals & Healthcare Q1 2020
... of listed generic drugs, lacks extensive detailsbut has already faced opposition from industry. Despite the government’s increased commitment to the health sector, a weakeconomic outlook and political uncertainty will limit external and internal investment in ... Read More
-
Nigeria Pharmaceuticals & Healthcare Q1 2020
... country’s attractiveness to innovative drugmakers. This is exacerbated by regulatory inefficiencies and high prevalence ofcounterfeit medicines. The goal of achievement of universal healthcare by 2030 will continue to be threatened by a number ofstructural issues. Read More
-
Lebanon Pharmaceuticals & Healthcare Q1 2020
... remain reliant onmedicine imports from more developed nearby markets in the short-to-medium term. The country’s public health sector hasbenefited from numerous supports schemes following the Syrian war, improving the populations access to healthcare. However,international aid ... Read More
-
Germany Pharmaceuticals & Healthcare Q1 2020
... to services, will continue tosupport this potential. However, we do caution that market access is now challenging, as authorities use a range of cost-containment measures and downward price pressures as a means of controlling state ... Read More
-
Kyrgyzstan Pharmaceuticals & Healthcare Q1 2020
... for drug sales limited to non-branded non-prescription and genericmedicines. The market will remain highly unattractive to innovative drugmakers also on account of the presence of counterfeitmedicines and challenges in supply and distribution across the country. Read More
-
Portugal Pharmaceuticals & Healthcare Q1 2020
... Portuguese market, thereby limiting their ability to capitalise on price variationsacross the EU. Portugal’s pharmaceutical market will grow over the forecast period, although a repressive pricing environment and aweak reimbursement profile will limit its attractiveness ... Read More
-
Tunisia Pharmaceuticals & Healthcare Q1 2020
... operations in the country owing to anumber of industry- and country-related risks. This is exacerbated by longstanding shortcomings in the healthcare system. As aresult, growth in the country's pharmaceutical and healthcare market will remain repressed. Read More
-
Tanzania Pharmaceuticals & Healthcare Q1 2020
... will have only a limited effect aslongstanding issues will remain in place. Low life expectancy and a young population will limit the uptake of high-value medicines.Nonetheless, with one of the highest birth rates in the ... Read More
